Welcome to our dedicated page for Lakewood-Amedex Biotherapeutics SEC filings (Ticker: LABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lakewood-Amedex Biotherapeutics filings document its status as a Nevada clinical-stage biotechnology company and Nasdaq-listed issuer focused on Bisphosphocin antimicrobial compounds. The company’s S-1 registration materials cover securities registration, business description, capitalization, risk factors, and offering-related disclosures for LABT common stock.
Material-event filings include governance disclosures such as director appointments and board matters reported under Form 8-K. The filing record also identifies public-company information related to corporate structure, pharmaceutical-preparations classification, executive offices, and securities-law reporting obligations.
Lakewood-Amedex Biotherapeutics Inc. (LABT) has filed a Form S-1 to register for resale up to 4,512,400 shares of common stock, all to be sold from time to time by a single selling stockholder upon conversion of its Series C Preferred Stock; the company states it will not receive any proceeds from these resales, though it will bear registration expenses.
These shares represent the additional common stock now issuable at the $1.00 per-share conversion floor that was not covered by an earlier S-1 that registered 937,500 shares already issued on conversion of 486,260 Series C Preferred shares. LABT previously raised $7.5 million gross ($6.8 million net) through the Series C financing and effected a one-for-ten reverse stock split on June 19, 2026. The company is a clinical-stage biotech developing its Bisphosphocin® antimicrobial platform, led by Nu-3 gel for infected diabetic foot ulcers, and reported no revenue and a $3.85 million net loss in 2025 with a going-concern explanatory paragraph in its audited financials.
Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotech developing antimicrobial therapies, led by Nu-3 for infected diabetic foot ulcers. For the six months ended June 30, 2026, it reported a net loss of $4.7 million, wider than $1.2 million a year earlier, as research and development expenses rose to $0.7 million and general and administrative expenses to $4.0 million, driven largely by public-company and advisory costs.
The company strengthened its balance sheet through a private placement of 937,500 Series C preferred shares, with $7.5 million gross and approximately $6.8 million net proceeds, and by converting $1.5 million of convertible notes and all Series A and B preferred (including dividends) into common stock. At June 30, 2026, cash and cash equivalents were $2.6 million, short-term certificates of deposit were $2.0 million, and working capital was about $4.2 million.
Despite this recapitalization, management states that recurring losses and expected cash use raise substantial doubt about continuing as a going concern within one year of issuance, as additional financing will be required beyond early 2027. Management also concludes disclosure controls were not effective due to material weaknesses in internal control over financial reporting.
Lakewood-Amedex Biotherapeutics Inc. reports that WFI Equity, LLC has filed as a significant holder of its common stock. WFI Equity beneficially owns 1,259,684 shares of common stock, representing 8.8% of the class, with sole voting and sole dispositive power over all of these shares and no shared power. The ownership percentage is based on 14,320,366 shares of common stock outstanding as of April 23, 2026, as referenced from a prior Form S-1. The filing is signed by Bradford Charles Lichota as Manager of WFI Equity, LLC.
Lakewood-Amedex Biotherapeutics Inc. reported a larger net loss of $4.7 million for the six months ended June 30, 2026, up from $1.2 million a year earlier, driven mainly by higher general and administrative costs associated with becoming a Nasdaq-listed company and ramping clinical activity.
Cash and cash equivalents rose to $2.6 million, with an additional $2.0 million in certificates of deposit, compared with $0.2 million in cash at year-end 2025. The improvement reflects a private placement of 937,500 Series C Convertible Preferred shares, providing $7.5 million in gross and about $6.8 million in net proceeds and converting prior preferred stock and convertible notes into common stock.
Despite the stronger balance sheet and working capital of about $4.2 million, management states that recurring losses and expected cash use raise substantial doubt about the company’s ability to continue as a going concern beyond early 2027 without additional financing. Management also concludes that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
Lakewood-Amedex Biotherapeutics Inc. is asking stockholders to approve several key actions at its September 22, 2026 virtual annual meeting. Stockholders will elect four directors to one-year terms; the slate includes CEO Kelvin Cooper and three independent directors.
The company seeks to amend its articles to increase authorized common stock from 12,500,000 to 100,000,000 shares. As of July 30, 2026, 2,369,688 shares were outstanding, with additional shares reserved for options and warrants; after the increase, approximately 97,387,493 shares would be authorized but unissued. A second capital proposal would authorize the board, at its discretion through September 22, 2027, to implement one or more reverse stock splits up to 1-for-20 to support Nasdaq Capital Market listing and potential financing flexibility.
The company also seeks to expand its 2020 Equity Incentive Plan from 183,505 to 400,000 shares to support employee and director equity awards. CBIZ CPAs P.C. is proposed for ratification as auditor; audit fees were $197,930 for 2025 and $107,427 for 2024. Executive agreements provide base salaries that step up after at least $5 million in private placement financing, immediate-vesting options at $0.39 per share, and severance of up to 18 months of salary upon certain terminations tied to a change in control.
Lindesfarne LLC reports beneficial ownership of 203,360 shares of Lakewood-Amedex Biotherapeutics Inc. common stock on a Schedule 13G. This represents 8.582% of the class, with sole voting and sole dispositive power over all 203,360 shares and no shared power.
The filing states that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Lakewood-Amedex Biotherapeutics Inc., and are not held in connection with any transaction having that purpose or effect.
Lakewood-Amedex Biotherapeutics Inc. is asking stockholders to approve several governance and capital-structure changes at the September 22, 2026 virtual annual meeting. As of the July 30, 2026 record date, 2,369,688 shares of common stock were outstanding, each with one vote.
Key proposals include: electing four directors for one-year terms; amending the articles of incorporation to increase authorized common stock from 12,500,000 to 100,000,000 shares, which would leave about 97,387,493 authorized but unissued; and authorizing the board to implement, at its discretion through September 22, 2027, one or more reverse stock splits up to a cumulative 1‑for‑20 ratio without reducing authorized shares.
The company also seeks to expand its 2020 Equity Incentive Plan from 183,505 to 400,000 shares and to ratify CBIZ CPAs P.C. as independent auditor for 2026, after paying $197,930 in audit fees in 2025. The board unanimously recommends voting in favor of all proposals.
Lakewood-Amedex Biotherapeutics Inc. furnished an investor presentation describing its Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials aimed at drug-resistant infections and antimicrobial resistance. The deck highlights Nu-3, a topically delivered antimicrobial gel in Phase 2-ready development for infected diabetic foot ulcers (iDFU), with supporting preclinical and early clinical data, safety profile, and a U.S.- and internationally focused Phase 2/Phase 3 regulatory strategy.
The presentation also outlines a development pipeline beyond Nu-3, a planned Phase 2a/2b iDFU trial with key 2026 milestones, and an intellectual property estate of 101 patents with protection extending up to 2044, along with details on the competitive landscape and experienced leadership team.
Lakewood-Amedex Biotherapeutics Inc. reports a Schedule 13G filing disclosing that HPW Investments Holding Ltd. beneficially owns 3,435,501 common shares, representing 24.04% of the outstanding common stock.
The filing states the ownership percentage is calculated based on 14,290,892 ordinary shares outstanding as of March 31, 2026. HPW has sole voting and sole dispositive power over the disclosed shares. The filing is signed by Dr. Martin Kleppe on behalf of the reporting person.
Lakewood-Amedex Biotherapeutics Inc. implemented a 1-for-10 reverse stock split of its common stock, effective at 4:01 p.m. Eastern Time on June 19, 2026. The company said shares will trade on a split-adjusted basis when Nasdaq opens on June 22, 2026 and that fractional shares will be rounded up.
The Certificate of Change also reduces the company’s authorized common shares to 12,500,000 and the company’s Nasdaq symbol remains LABT; the security has a new CUSIP 51255A201.